Cargando…

A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease

Lewy body diseases are neurodegenerative disorders characterized by Lewy bodies in the brain. Lewy body dementia (LBD) refers to two forms of Lewy body disease: Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB). Tau is a cytoskeletal protein found in neurofibrillary tangles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Benjamin R., Nelson, Kathryn M., Kemper, Lisa J., Leinonen-Wright, Kailee, Petersen, Ashley, Keene, C. Dirk, Ashe, Karen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668119/ https://www.ncbi.nlm.nih.gov/pubmed/31362787 http://dx.doi.org/10.1186/s40478-019-0765-8

Ejemplares similares

Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer’s disease, Huntington’s disease, or Lewy Body dementia
por: Hlynialuk, Chris, et al.
Publicado: (2022)

A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
por: Liu, Peng, et al.
Publicado: (2020)

Author Correction: A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals
por: Liu, Peng, et al.
Publicado: (2020)

A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington’s disease patients
por: Liu, Peng, et al.
Publicado: (2019)

The molecular implications of a caspase-2-mediated site-specific tau cleavage in tauopathies
por: Liu, Peng, et al.
Publicado: (2021)

Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
por: Chen, Qin, et al.
Publicado: (2022)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

A toxic subset of soluble α-synuclein species in dementia with Lewy body
por: Castillo-Carranza, Diana L
Publicado: (2020)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
por: Abdelnour, Carla, et al.
Publicado: (2020)

Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
por: Miller, Rebecca L., et al.
Publicado: (2022)

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
por: Alam, John J., et al.
Publicado: (2023)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Caspase-Cleaved Tau Co-Localizes with Early Tangle Markers in the Human Vascular Dementia Brain
por: Day, Ryan J., et al.
Publicado: (2015)

Neuroimaging in Lewy body dementia
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Microbleeds in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2020)

Advances in dementia with Lewy bodies
por: Armstrong, Melissa J.
Publicado: (2021)

Neuroimaging in Dementia With Lewy Bodies
por: Saha, Abhishikta, et al.
Publicado: (2021)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET
por: Nedelska, Zuzana, et al.
Publicado: (2018)

Tau and Caspase 3 as Targets for Neuroprotection
por: Idan-Feldman, Anat, et al.
Publicado: (2012)

Neuroimaging characteristics of dementia with Lewy bodies
por: Mak, Elijah, et al.
Publicado: (2014)

Comprehensive treatment of dementia with Lewy bodies
por: Boot, Brendon P
Publicado: (2015)

Neurophysiological biomarkers for Lewy body dementias
por: Cromarty, Ruth A., et al.
Publicado: (2016)

Exome sequencing in dementia with Lewy bodies
por: Keogh, M J, et al.
Publicado: (2016)

Clinical prevalence of Lewy body dementia
por: Kane, Joseph P. M., et al.
Publicado: (2018)

Dementia with Lewy bodies: an update and outlook
por: Outeiro, Tiago Fleming, et al.
Publicado: (2019)

Young-Onset Dementia with Lewy Bodies
por: Aiba, Yosuke, et al.
Publicado: (2018)

Pharmacological Management of Dementia with Lewy Bodies
por: Hershey, Linda A., et al.
Publicado: (2019)

Spatial Perseveration in Dementia with Lewy Bodies
por: Assal, Frédéric, et al.
Publicado: (2007)

Clinical diagnosis of Lewy body dementia
por: Surendranathan, Ajenthan, et al.
Publicado: (2020)

Gut microbiota in dementia with Lewy bodies
por: Nishiwaki, Hiroshi, et al.
Publicado: (2022)

Onset matters in dementia with Lewy bodies
por: Müller, Sebastian Johannes, et al.
Publicado: (2023)

β-Amyloid PET and neuropathology in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2020)

Genotype-Specific Differences between Mouse CNS Stem Cell Lines Expressing Frontotemporal Dementia Mutant or Wild Type Human Tau
por: Orr, Miranda E., et al.
Publicado: (2012)

Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice
por: Gamache, Julia, et al.
Publicado: (2019)

The temporal onset of the core features in dementia with Lewy bodies
por: Choudhury, Parichita, et al.
Publicado: (2021)

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
por: Jellinger, Kurt A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d8d51dsooip75kj97soj2kq1fb